News
BMS immunotherapy-chemo combination gets NICE recommendation
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Opdivo.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Opdivo.